Dual Inhibitors Targeting DNA and Histone Deacetylases

Abstract

Histone deacetylases (HDACs) regulate the acetylation status of histones and structural status of chromatin. The chromatin structure becomes relaxed after inhibition of HDAC, leading to DNA exposed to DNA disrupting agents, and eventually causing DNA dysfunction. Recently, more and more dual inhibitors targeting DNA and HDACs have been reported to be applied to cancer treatment. In this review, we describe the current status of dual inhibitors targeting DNA and HDACs, summarize their pharmacological characters, and predict their further trend in the field.

Keywords

DNA - HDAC - dual-targeting - antitumor agent

• References

• 1 Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13 (10) 714-726
• 2 He B, Lu C, Zheng G. , et al. Combination therapeutics in complex diseases. J Cell Mol Med 2016; 20 (12) 2231-2240
• 3 Bayat Mokhtari R, Homayouni TS, Baluch N. , et al. Combination therapy in combating cancer. Oncotarget 2017; 8 (23) 38022-38043
• 4 Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007; 12 (1-2): 34-42
• 5 Rosini M. Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem 2014; 6 (05) 485-487
• 6 Bhaduri S, Ranjan N, Arya DP. An overview of recent advances in duplex DNA recognition by small molecules. Beilstein J Org Chem 2018; 14: 1051-1086
• 7 Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2011; 18 (11) 1658-1671
• 8 Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63 (21) 7291-7300
• 9 Burchenal JH, Kalaher K, Dew K. , et al. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochimie 1978; 60 (09) 961-965
• 10 Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000; 38 (04) 291-304
• 11 Schabel Jr FM. Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 1976; 60 (06) 665-698
• 12 Kimball DB, Haley MM. Triazenes: a versatile tool in organic synthesis. Angew Chem Int Ed Engl 2002; 41 (18) 3338-3351
• 13 Fong LY, Bevill RF, Thurmon JC, Magee PN. DNA adduct dosimetry and DNA repair in rats and pigs given repeated doses of procarbazine under conditions of carcinogenicity and human cancer chemotherapy respectively. Carcinogenesis 1992; 13 (11) 2153-2159
• 14 Martínez R, Chacón-García L. The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem 2005; 12 (02) 127-151
• 15 Lerman LS. Structural considerations in the interaction of DNA and acridines. J Mol Biol 1961; 3: 18-30
• 16 Mišković K, Bujak M, Baus Lončar M, Glavaš-Obrovac L. Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs. Arh Hig Rada Toksikol 2013; 64 (04) 593-602
• 17 Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013; 8 (01) 82-95
• 18 Zhang B, Li X, Li B, Gao C, Jiang Y. Acridine and its derivatives: a patent review (2009 - 2013). Expert Opin Ther Pat 2014; 24 (06) 647-664
• 19 Khalaf AI, Al-Kadhimi AAH, Ali JH. DNA minor groove binders-inspired by nature. Acta Chim Slov 2016; 63 (04) 689-704
• 20 Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007; 18 (06) 497-503
• 21 Liu C, Ding H, Li X. , et al. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med 2015; 7 (04) 438-449
• 22 Xie R, Li Y, Tang P, Yuan Q. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity. Bioorg Med Chem Lett 2017; 27 (18) 4415-4420
• 23 Xie R, Tang P, Yuan Q. Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. MedChemComm 2017; 9 (02) 344-352
• 24 Griffith D, Morgan MP, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem Commun (Camb) 2009; (44) 6735-6737
• 25 McGivern TJP, Slator C, Kellett A, Marmion CJ. Innovative DNA-targeted metallo-prodrug strategy combining histone deacetylase inhibition with oxidative stress. Mol Pharm 2018; 15 (11) 5058-5071
• 26 Chen J, Li D, Li W. , et al. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors. Bioorg Med Chem 2018; 26 (14) 3958-3966
• 27 Ling Y, Xu C, Luo L. , et al. Novel β-carboline/hydroxamic acid hybrids targeting both histone deacetylase and DNA display high anticancer activity via regulation of the p53 signaling pathway. J Med Chem 2015; 58 (23) 9214-9227